These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36982500)

  • 1. Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma.
    Wang J; Wang Y; Pan H; Zhao L; Yang X; Liang Z; Shen X; Zhang J; Yang J; Zhu Y; Xun J; Liang Y; Lin Q; Liang H; Li M; Zhu H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ; Hwang SJ; Jeong EH; Chang MH
    J Microbiol; 2024 Jul; 62(7):555-568. PubMed ID: 38700775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
    Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
    Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
    Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
    Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.
    Zhou X; Li J; Wang Z; Chen Z; Qiu J; Zhang Y; Wang W; Ma Y; Huang N; Cui K; Li J; Wei YQ
    Neoplasia; 2013 May; 15(5):544-53. PubMed ID: 23633926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y; Liu Q; Zuo T; Wei G; Jiao S
    Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
    Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
    Liu X; Ranganathan R; Jiang S; Fang C; Sun J; Kim S; Newick K; Lo A; June CH; Zhao Y; Moon EK
    Cancer Res; 2016 Mar; 76(6):1578-90. PubMed ID: 26979791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer.
    Li G; Liao G; Xie J; Liu B; Li X; Qiu M
    Respirology; 2023 Sep; 28(9):869-880. PubMed ID: 37376985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.